INOZYME PHARMA, INC. Earnings Per Share, Basic and Diluted
INOZYME PHARMA, INC. reported Earnings Per Share, Basic and Diluted of -$0.71 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- INOZYME PHARMA, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.71.
- INOZYME PHARMA, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.79.
- INOZYME PHARMA, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.60.
- INOZYME PHARMA, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.53.
- INOZYME PHARMA, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.40.
- INOZYME PHARMA, INC. earnings per share, basic and diluted for fiscal 2020 was -$5.11.
- INOZYME PHARMA, INC. earnings per share, basic and diluted for fiscal 2019 was -$16.67.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.71 10-Q · filed 2022-05-10 | -$1.51 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.11 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.64 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2021-12-31 | -$0.79 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.40 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.93 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$2.40 10-K · filed 2022-03-15 |
| 2021-09-30 | -$0.60 10-Q · filed 2021-11-09 | -$1.14 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.61 10-Q · filed 2021-11-09 | -$2.08 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$0.53 10-Q · filed 2021-08-11 | -$1.01 10-Q · filed 2021-08-11 | -$1.48 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$2.84 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-03-31 | -$0.47 10-Q · filed 2022-05-10 | -$0.95 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$2.32 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$3.61 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2020-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$1.89 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$3.41 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$5.11 10-K · filed 2022-03-15 |
| 2020-09-30 | -$1.55 10-Q · filed 2021-11-09 | -$3.88 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$6.57 10-Q · filed 2021-11-09 | -$9.53 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-06-30 | -$7.57 10-Q · filed 2021-08-11 | -$14.01 10-Q · filed 2021-08-11 | -$19.48 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$22.90 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-03-31 | -$6.42 10-Q · filed 2021-05-12 | -$11.86 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$15.25 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$18.85 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2019-12-31 | -$5.44 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$8.82 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$12.40 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$16.67 10-K · filed 2021-03-25 |
| 2019-09-30 | -$3.38 10-Q · filed 2020-11-12 | -$6.94 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$11.20 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$3.57 10-Q · filed 2020-09-03 | -$7.83 10-Q · filed 2020-09-03 |